Paloma García de la Peña Lefebvre-rekin lankidetzan egindako argitalpenak (14)

2022

  1. Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort

    The Lancet Rheumatology, Vol. 4, Núm. 11, pp. e785-e794

2019

  1. Overlap myositis, a distinct entity beyond primary inflammatory myositis: A retrospective analysis of a large cohort from the REMICAM registry

    International Journal of Rheumatic Diseases, Vol. 22, Núm. 8, pp. 1393-1401

2017

  1. Multicenter registry on inflammatory myositis from the Rheumatology Society in Madrid, Spain: Descriptive Analysis

    Reumatologia Clinica, Vol. 13, Núm. 6, pp. 331-337

  2. What have multicentre registries across the world taught us about the disease features of systemic sclerosis?

    Journal of Scleroderma and Related Disorders, Vol. 2, Núm. 3, pp. 169-182

2016

  1. Influence of TYK2 in systemic sclerosis susceptibility: A new locus in the IL-12 pathway

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 8, pp. 1521-1526

2015

  1. Efficacy of Raynaud’s phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review

    Rheumatology International, Vol. 35, Núm. 9, pp. 1447-1459

2013

  1. The role of the NLRP1 gene in systemic sclerosis: Areplication study

    Clinical and Experimental Rheumatology

2011

  1. Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis

    Annals of the Rheumatic Diseases, Vol. 70, Núm. 3, pp. 454-462

  2. Is there a role for TNF-α antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique

    Clinical and Experimental Rheumatology, Vol. 29, Núm. 2 SUPPL. 65

  3. No evidence for association between the CCR5/Delta32CCR5 polymorphism and systemic sclerosis

    Clinical and Experimental Rheumatology

2010

  1. BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians

    Annals of the Rheumatic Diseases, Vol. 69, Núm. 4, pp. 700-705

  2. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database

    Journal of Rheumatology, Vol. 37, Núm. 7, pp. 1488-1501

2009

  1. EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group (EUSTAR)

    Annals of the Rheumatic Diseases, Vol. 68, Núm. 5, pp. 620-628

2007

  1. Registro Español de Acontecimientos Adversos de Terapias Biológicas en Enfermedades Reumáticas (BIOBADASER): Informe de la situación, 26 de enero de 2006

    Reumatologia Clinica, Vol. 3, Núm. 1, pp. 4-20